1372540-25-4

Basic information

• Product Name: GSK2636771
• Synonyms: GSK2636771;2-Methyl-1-[[2-Methyl-3-(trifluoroMethyl)phenyl]Methyl]-6-(4-Morpholinyl)-1H-benziMidazole-4-carboxylic acid;GSK2636771/GSK-2636771;1H-Benzimidazole-4-carboxylic acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-;2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid GSK2636771;GSK 2636771 dihydrochloride;2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic;2-METHYL-1-[[2-METHYL-3-(TRIFLUOROMETHYL)PHENYL]METHYL]-6-MORPHOLIN-4-YLBENZIMIDAZOLE-4-CARBOXYLIC ACID
• CAS NO: 1372540-25-4
• Molecular Formula: C₂₂H₂₂F₃N₃O₃
• Molecular Weight: 433.4235896
• Product Categories: PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K
• Mol File: 1372540-25-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 641.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.38
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: -2.70±0.30(Predicted)
• CAS DataBase Reference: GSK2636771(CAS DataBase Reference)
• NIST Chemistry Reference: GSK2636771(1372540-25-4)
• EPA Substance Registry System: GSK2636771(1372540-25-4)

Safety Data

• Hazardous Substances Data: 1372540-25-4(Hazardous Substances Data)

Usage

Uses

GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Upstream product

• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 1372540-21-0 methyl 2-methyl-5-(4-morpholinyl)-1H-benzimidazole-7-carboxylate 
• 1203486-58-1 methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate 
• 874301-23-2 3-amino-5-chloro-2-nitrobenzoic acid methyl ester 
• 1372540-24-3 methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 

Downstream Products

• 1372540-33-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxamide 
• 1372540-91-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt 
• 1372540-93-6 ethyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 
• 1372540-34-5 C₂₂H₂₁ClF₃N₃O₂ 
• 1372540-32-3 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazole 

Relevant articles and documents

COMBINATION TREATMENT FOR CANCER

Disclosed herein is a method of treatment involving the combination of an OX40 antigen binding protein (e.g., an anti-OX40 agonist antibody) and a PI3Kb inhibitor for use in treating a cancer, such as a PTEN deficient cancer.

COMBINATION DRUG THERAPY

A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a PI3K? inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or PI3K? is beneficial, e.g., cancer.